A Phase I/II Study of HE3235 in Patients With Prostate Cancer

Completed · Phase 1/Phase 2

Conditions studied: Prostate Cancer

In brief

This is a phase I/II, open-label, dose escalation study of HE3235 administered orally to patients with advanced prostate cancer who have failed hormone therapy and at least one taxane based chemotherapy regimen.

Key facts

Study ID

NCT00716794

Run by

Harbor Therapeutics

People needed

64

Starts

2008-07-01

Expected to finish

2011-03-01

Last updated by the study team

2011-03-09

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Study site — Scottsdale, Arizona, United States
• Study site — Encinitas, California, United States
• Study site — Roseville, California, United States
• Study site — San Francisco, California, United States
• Study site — New York, New York, United States
• Study site — Charlotte, North Carolina, United States
• Study site — San Antonio, Texas, United States
• Study site — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.